A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: Evidence of efficacy continues to mount

Leukemia Research

Volumn 34, Issue 10, 2010, Pages

  Fesler, Mark J ^a   Richart, John M ^a   Petruska, Paul J ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CD34 ANTIGEN; CD4 ANTIGEN; CD7 ANTIGEN; CLADRIBINE; CYTARABINE; ESTERASE; ETOPOSIDE; FLT3 LIGAND; HLA DR ANTIGEN; IDARUBICIN; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; SORAFENIB; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ANTIGEN EXPRESSION; BLAST CELL; BONE MARROW BIOPSY; CASE REPORT; CAUCASIAN; CHROMOSOME 14Q; CHROMOSOME 16Q; CHROMOSOME 1Q; CHROMOSOME 7Q; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 7; CHROMOSOME TRANSLOCATION X; CHROMOSOME XP; CLINICAL FEATURE; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOCHEMISTRY; CYTOGENETICS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FLOW CYTOMETRY; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; SKIN BRUISING; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BLAST CRISIS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; POINT MUTATION; PROTEIN KINASE INHIBITORS; PYRIDINES; RECURRENCE;

EID: 77955983002     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.03.046     Document Type: Letter

References (5)

1. Metzelder S., Wang Y., Wollmer E., Wanzel M., Teichler S., Chaturvedi A., et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113:6567-6571.
2. Levis M., Ravandi F., Wang E.S., Baer M.R., Perl A., Coutre S., et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for FLT3 mutant AML patients in first relapse [abstract]. Blood, ASH Ann Meet Abstr 2009, 114. [22: abstract 788].
3. Pratz K.W., Sato T., Murphy K.M., Stine A., Rajkhowa T., Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010, 115:1425-1432.
4. Preisler H.D., Raza A., Azarnia N., Rakowsky I., Barcos M., Browman G., et al. Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy. Eur J Cancer Clin Oncol 1985, 21(5):563-571.
5. Ravandi F., Cortes J.E., Jones D., Faderl S., Garcia-Manero G., Konopleva M.Y., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with Acute Myeloid Leukemia. J Clin Oncol 2010, [epublished March 8].